FindTrial
Sign In

Dose-Effect Analysis of Rituximab in Renal Diseases

Analysis of Rituximab Dosages and Efficacy in the Treatment of Renal Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106194
Enrollment
Unknown
Registered
2025-07-18
Start date
2025-07-21
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Diseases

Interventions

Ultra Low Dose Group:None
Standard Dose Group:None

Sponsors

Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.2010.01.01-2022.05.15 Patients with kidney diseases (including NS, MN, lupus nephritis, etc.) treated with RTX in West China Hospital, Sichuan University 2. Have pathological results of renal biopsy; 3. Age>=14 years; 4. Follow-up time at least >=1 year; 5. Very low dose group: single RTX administration of 100mg or 200mg, standard dose group: single RTX administration > = 500mg or 375mg/cm^2 body surface area.

Exclusion criteria

Exclusion criteria: 1. Patients treated with RTX for non-renal disease reasons; 2. Patients with end-stage renal disease (eGFR<15 mL/min/1.73m^2) or undergoing kidney transplantation; 3. More than 20% of the data is missing.

Design outcomes

Primary

MeasureTime frame
Complete Remission Rate (CR) ;Partial Remission Rate (PR);—

Secondary

MeasureTime frame
Duration of Remission;Relapse Rate;Renal Function Changes ;Adverse Events;—

Countries

China

Contacts

Public ContactChen Liu

West China Hospital of Sichuan University

chenliu@scu.edu.cn+86 187 0817 8871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026